Bioxytran, Inc.
BIXT
$0.109
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -63.52% | 53.79% | |||
| Depreciation & Amortization | -34.48% | 93.33% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.25% | 41.27% | |||
| Operating Income | -5.25% | -41.27% | |||
| Income Before Tax | -161.87% | -31.73% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -161.87% | -31.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -168.78% | -28.34% | |||
| EBIT | -5.25% | -41.27% | |||
| EBITDA | -5.49% | -41.05% | |||
| EPS Basic | -181.48% | -74.19% | |||
| Normalized Basic EPS | -43.94% | -247.37% | |||
| EPS Diluted | -181.48% | -74.19% | |||
| Normalized Diluted EPS | -43.94% | -247.37% | |||
| Average Basic Shares Outstanding | -4.40% | -26.47% | |||
| Average Diluted Shares Outstanding | -4.40% | -26.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||